What it is: A small molecule that blocks an enzyme linked to fat cell activity and NAD+ metabolism, included here because it is commonly studied alongside peptide longevity protocols.
Research suggests: Preclinical studies show it may reduce body fat and improve metabolic markers without affecting lean muscle mass.
Best for: Metabolic and longevity researchers
Key thing to know: Not technically a peptide and has no human clinical trial data yet; all meaningful evidence is from preclinical studies.
What is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme expressed primarily in adipose tissue that plays a regulatory role in NAD+ metabolism and fat cell differentiation. It is not technically a peptide. It is included in this library because it is commonly researched alongside peptide protocols in longevity and metabolic research settings, and because its proposed mechanism connects directly to the NAD+ biology that underlies several established peptide research areas.
NNMT activity in fat tissue has been linked to obesity, reduced cellular NAD+ availability, and impaired adipocyte metabolism. The scientific rationale for inhibiting NNMT is that reducing its activity may redirect more nicotinamide toward NAD+ synthesis, improving metabolic function in fat cells while also reducing fat cell size and number. This places 5-Amino-1MQ at the intersection of two active research areas: NAD+ biology and adipose tissue metabolism.
Research interest grew significantly following publications from University of Texas Southwestern Medical Center showing dramatic reductions in fat mass and metabolic improvements in mouse models fed high-fat diets. As of 2025, no human clinical trial data has been published.
How it works.
NNMT catalyzes the methylation of nicotinamide using SAM (S-adenosylmethionine) as the methyl donor. This reaction converts nicotinamide into 1-methylnicotinamide, removing it from the pool available for NAD+ synthesis. In fat tissue, high NNMT activity has two consequences: reduced NAD+ precursor availability, which impairs mitochondrial function and energy metabolism in adipocytes, and altered methylation balance, as SAM consumption by NNMT reduces the capacity for other methylation reactions that regulate gene expression in fat cells.
By inhibiting NNMT, 5-Amino-1MQ is proposed to increase the nicotinamide pool available for NAD+ synthesis, restore methylation balance, and improve adipocyte metabolic function. In mouse studies, this translated to reduced fat cell size, reduced fat mass even on high-fat diets, and improvements in metabolic markers including insulin sensitivity and lipid profiles. The animals treated with 5-Amino-1MQ showed measurably higher energy expenditure than controls, suggesting increased mitochondrial activity in fat tissue.
Think of NNMT as a drain that pulls nicotinamide away from NAD+ production specifically in fat tissue. 5-Amino-1MQ closes that drain, allowing more nicotinamide to become NAD+. The connected improvement in fat cell biology is the proposed downstream effect. The mechanistic logic is scientifically sound and connects to well-established NAD+ biology.
Whether the effect size seen in mice translates to humans at comparable doses remains the central unanswered question.
What the research shows.
The published evidence for 5-Amino-1MQ is entirely preclinical, based on mouse models. The key studies from University of Texas Southwestern, published in peer-reviewed journals, showed that oral administration of 5-Amino-1MQ to mice on high-fat diets significantly reduced fat mass accumulation, improved insulin sensitivity, and increased energy expenditure compared to untreated controls. The results were striking in magnitude and the proposed mechanism is biologically coherent and connected to established NAD+ science.
The limitation is fundamental: all of this data comes from mice. The history of metabolic research is filled with compounds that produced compelling mouse data and then failed to demonstrate comparable effects in human trials. The translation from mouse models to human physiology is particularly uncertain for compounds acting on adipose tissue metabolism, as human adipose biology differs from rodent adipose biology in ways that are not fully characterized.
No Phase 1 safety data, no human pharmacokinetic data, and no clinical efficacy trials have been published as of 2025. This creates a situation where the mechanistic rationale is interesting and the animal data is encouraging, but the entire human profile is unknown. That is the defining characteristic of a preliminary-rated compound in this library.
Biomarkers to review first.
Given 5-Amino-1MQ's proposed effects on fat metabolism and NAD+ biology, the following biomarkers provide the most relevant baseline context for any research consideration. Understanding your metabolic starting point is essential before evaluating whether this compound is appropriate to research.
What it's commonly researched with.
In research and longevity protocol discussions, 5-Amino-1MQ frequently appears alongside compounds that share its metabolic and NAD+ biology focus. The combinations below reflect what researchers discuss in this context, not recommendations for use.